ET-targeted opportunity Citryll is developing an ET-targeting therapy aimed at immune-mediated inflammatory diseases, with early clinical work on the lead antibody CIT-013 for rheumatoid arthritis and hidradenitis suppurativa. Potential sales angles include expanding into other inflammatory conditions where NET/NETosis modulation is therapeutic.

Clinical leadership The company has appointed a Chief Medical Officer and is advancing CIT-013 into clinical trials, signaling readiness for partnered development and potential co-development discussions with large pharma to accelerate trial execution and broader indications.

Strategic funding Significant Series B funding and involvement from major investors (JJDC, Forbion, Novartis Venture Fund) alongside leadership changes create opportunities for strategic partnerships, licensing deals, and joint ventures to co-develop or co-commercialize ET-targeting therapies.

Board & governance New non-executive directors from major investors bring governance and strategic networks that can facilitate introductions to potential partners, CROs, and research collaborations in immunology and biotech ecosystems.

Global potential With a focus on broad inflammatory applications and a novel drug class, Citryll presents cross-border partnering opportunities for translational programs, while existing investor credibility can help open access to international clinical development and commercialization channels.